TOBRAMYCIN
AND
TICARCILLIN
THERAPY
FOR
EXACERBATIONS
OF
PULMONARY
DISEASE
IN
PATIENTS
WITH
CYSTIC
FIBROSIS
PATIENTS
WHO
HAD
CYSTIC
FIBROSIS
AND
ACUTE
INFECTIOUS
EXACERBATIONS
OF
PULMONARY
DISEASE
PRODUCED
BY
PSEUDOMONAS
AERUGINOSA
WERE
TREATED
WITH
A
COMBINATION
OF
TOBRAMYCIN
AND
TICARCILLIN
P
AERUGINOSA
RECOVERED
FROM
PATIENTS
WAS
INHIBITED
BY
LOWER
CONCENTRATIONS
OF
BOTH
OF
THESE
DRUGS
THAN
OF
GENTAMICIN
OR
CARBENICILLIN
THIRTEEN
COURSES
OF
TREATMENT
WERE
ADMINISTERED
TO
11
PATIENTS
MEAN
144
DAYS
A
FAVORABLE
RESPONSE
WAS
SEEN
IN
11
OF
12
COMPLETED
COURSES
OF
TREATMENT
IMPROVEMENT
WAS
ASSOCIATED
WITH
DECREASES
IN
WHITE
BLOOD
CELL
COUNT
TEMPERATURE
AND
SEDIMENTATION
RATE
ADVERSE
REACTIONS
WERE
UNCOMMON
ALTHOUGH
P
AERUGINOSA
WAS
NOT
ERADICATED
FROM
THE
SPUTUM
THE
CLINICAL
RESULTS
SUGGEST
THAT
THE
COMBINATION
OF
TOBRAMYCIN
AND
TICARCILLIN
MAY
BE
PARTICULARLY
USEFUL
FOR
TREATMENT
OF
ACUTE
EXACERBATIONS
OF
PULMONARY
DISEASE
IN
PATIENTS
WITH
CYSTIC
FIBROSIS
FROM
WHOM
P
AERUGINOSA
IS
ISOLATED
